Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median

Ther Adv Med Oncol. 2020 Jun 3:12:1758835920930643. doi: 10.1177/1758835920930643. eCollection 2020.
No abstract available

Keywords: Kaplan–Meier estimate; T-cell; antigen; axicabtagene ciloleucel; diffuse; large B-cell; lymphoma; progression-free survival; receptors.